$73.22▼ 2.60 (3.43%)
Real-time prices · US MarketsHigh-quality business with 45% return on equity and 27% profit margins.
Quality
9.3
Health
6.2
Growth
6.6
Valuation
8.4
Sentiment
7
Analyst Target
$116.78
▲ +59.5% from current
Price Chart
Latest News
Fundamentals
Trailing P/E
16.8×
price-to-earnings
Forward P/E
22.2×
next 12 months est.
Market Cap
$2.5B
market capitalization
Div Yield
—
dividend yield
Profit Margin
27.0%
net profit margin
Gross Margin
59.1%
revenue minus COGS
ROE
45.2%
return on equity
Beta
1.88
vs S&P 500
52-Week Range
$60 — $156
annual min — max
EPS — Estimate vs Actual
Frequently Asked Questions
What do analysts say about TransMedics Group, Inc. right now?
TransMedics Group, Inc.'s Q·Score is 7.6/10 (Bullish), reflecting its current fundamentals, analyst data, and valuation metrics. High-quality business with 45% return on equity and 27% profit margins. This is an informational data summary only and does not constitute financial advice. Always do your own research before making any investment decision.
What is the analyst price target for TMDX?
The consensus price target for TMDX is $116.78, based on ratings from 9 Wall Street analysts. This is 59.5% above the current price of $73.22. Price targets are forward-looking estimates and not guarantees of future performance.
Is TMDX overvalued or undervalued?
TransMedics Group, Inc. (TMDX) scores favorably on valuation metrics relative to sector peers and analyst targets. Its forward P/E ratio stands at 22.2×. The consensus analyst price target of $116.78 is 59% above the current price.
When does TransMedics Group, Inc. report its next earnings?
TransMedics Group, Inc.'s next earnings report is expected on approximately July 30, 2026.
What is TransMedics Group, Inc.'s profit margin?
TransMedics Group, Inc. has a net profit margin of 27.0%, which is considered high and reflects strong pricing power. Its gross margin stands at 59.1%, indicating a high-margin business model.
Is TransMedics Group, Inc.'s revenue growing?
TransMedics Group, Inc. is reporting strong year-over-year growth of 21.2%. However, earnings declined 71.5%, which warrants monitoring.
How much debt does TransMedics Group, Inc. have?
TransMedics Group, Inc. has a debt-to-equity ratio of 1.75×, reflecting a moderately high debt load — watch cash flow coverage. Its current ratio is 6.74×, indicating comfortable short-term liquidity.